Antitrust Compliance and Clinical Integration: Assessing Anti-Competitiveness of Collaborations, Minimizing Risk of Agency Challenges

Recording of a 90-minute CLE webinar with Q&A

Conducted on Tuesday, June 20, 2017

Recorded event now available

or call 1-800-926-7926
Program Materials

This CLE webinar will provide healthcare counsel with an examination of the latest developments with respect to clinical integration programs, as well as the FTC and DOJ assessment processes. The panel will offer best practices for effective clinical integration while mitigating antitrust concerns.


Although there is much talk of change in Washington, D.C. when it comes to healthcare, one consistency is that healthcare providers around the country continue to seek out ways to better collaborate and coordinate care. Accountable care organizations and other forms of clinical integration are the most common types of collaborations other than mergers and acquisitions. However, competitor collaborations can raise antitrust concerns. The FTC, DOJ, state attorneys general and other market participants are scrutinizing these clinical integration arrangements to ensure compliance with antitrust laws.

The panel, including current practitioners and current and former FTC enforcers, will describe how the FTC investigates collaborations among providers such as ACOs and clinically integrated networks. They will discuss collaborative activities that are unlikely to raise antitrust concerns, and the types of situations that are likely to prompt an investigation. They will address how to reduce antitrust risks in forming and operating a physician network, joint venture or ACO, and how best to respond to an antitrust investigation if one occurs.

Listen as our authoritative panel provide practical guidance on how to assess the antitrust risks of a provider collaboration and how to reduce the likelihood of an antitrust investigation or challenge.



  1. Antitrust overview
  2. Antitrust assessment of provider collaborations
    1. Is there sufficient financial or clinical integration?
    2. Will the network have market power—how does one go about determining product and geographic markets, or is that even necessary?
    3. Exclusive vs. non-exclusive networks
    4. How does one document potential cost and quality efficiencies?
    5. What conduct creates “red flags?”
  3. Addressing some common questions
    1. How does the network know that it is sufficiently integrated?
    2. When can joint negotiations begin?
    3. Should the network work with health plans—and if so, how?
    4. How important is evidence of cost or quality gains?
    5. Does working with a hospital raise or lower the antitrust risks?
    6. What if prices go up?
    7. Should the network seek an advisory opinion?
    8. And many more …


The panel will review these and other key issues:

  • What are the lessons from recent cases and the FTC’s recent advisory opinions regarding clinical integration programs?
  • What elements should be included in a clinically integrated provider network within the meaning of antitrust law?
  • What are best practices for effective clinical integration and avoiding antitrust problems?


Saralisa C. Brau
Saralisa C. Brau
Deputy Assistant Director, Health Care Division
Federal Trade Commission

Ms. Brau leads investigations and litigation involving alleged violations of the antitrust laws by pharmaceutical...  |  Read More

Leibenluft, Robert
Robert F. Leibenluft

Hogan Lovells US

Mr. Leibenluft's practice is devoted entirely to health and antitrust matters, including counseling and litigation...  |  Read More

Oliver, Leigh
Leigh L. Oliver

Hogan Lovells US

Ms. Oliver's practice is devoted to antitrust law, including counseling and litigation on a wide range of legal and...  |  Read More

Other Formats
— Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include program handouts. To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video